Halozyme Therapeutics | HALO - La Marge Brute Sur Les Ventes





La Marge Brute Sur Les Ventes Changement Date
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Agios Pharmaceuticals USD 18.09M 6.89M 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amarin USD 23.17M 961K 2025-12
Amgen USD 6.48B 307M 2025-09
Baxter International USD 577M 373M 2025-12
Cara Therapeutics USD 2.57M 1.11M 2025-03
Cytokinetics USD 17.76M 15.82M 2025-12
DBV Technologies USD 2.77M 33.21M 2025-09
Eli Lilly USD 14.59B 1.48B 2025-09
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Intrexon USD -297K 167K 2024-06
Ionis Pharmaceuticals USD 195M 40M 2025-12
MannKind USD 78.31M 76.21M 2025-12
Minerva Neurosciences -4.27M 26.79M 2024-12
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Rigel Pharmaceuticals USD 28.49M 7.01M 2024-06
United Therapeutics USD 315.5M 286.6M 2025-12
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12